Melphalanflufenamid (2) – Pepaxti®
Multiple myeloma, refractory, after 2 prior therapies, combination with dexamethasone
Characteristics
| Start date | 15.01.2024 |
|---|---|
| Resolution | 04.04.2024 |
| INN | Melphalanflufenamid |
| Brand name | Pepaxti® |
| Pharm. company | Oncopeptides AB |
| G-BA Procedure ID | D-1039 |
| Therapeutic area | Oncological diseases Multiple myeloma (MM) |
| Reason for procedure | not completed: discontinued |
| Regulatory status | authorisation withdrawn by EMA |
Associated procedures
<< List of all resolutions